http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014133414-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a968d4ce16bddd0cd4ab7e63f09c8d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_873b0b32344e0ba1762423ff4ddbfa9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a86291c63f245efb1eecb233329fa1e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D267-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D267-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 |
| filingDate | 2014-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b23946155b676da5b39d64cc6d0b587 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff14687f359b6213a5686ab20a5e1dc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a6518fc7852d9800ccab7e4994e7691 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a2f7627ae85446a4ad68a286492a244 |
| publicationDate | 2014-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2014133414-A3 |
| titleOfInvention | Heterocyclic tgr5 bile acid receptor agonists, pharmaceutical composition, methods for the production and use thereof |
| abstract | 1. Compounds of general formula I, or racemic mixtures thereof, or individual optical isomers thereof, or pharmaceutically acceptable salts and/or hydrates thereof, wherein: X is the amino group R'R''N, optionally substituted or unsubstituted with identical substituents R' and R'', or a substituted oxy group; the R'R''N group is a non-aromatic azaheterocycle, preferably azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, homopiperidine or homopiperazine; the amino group substituents R' and R'' are hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkenyl, cycloalkenyl, alkynyl, acyl, aroyl, heteroaroyl, alkylsulphonyl, arylsulphonyl, heteroarylsulphonyl, alkoxycarbonyl, aryloxycarbonyl, araloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, heterocyclylaminocarbonyl, alkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocyclylaminothiocarbonyl, optionally substituted aminosulphonyl, the R'R''N group may be a non-aromatic azaheterocycle, preferably azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, homopiperidine or homopiperazine; and the substituted oxy group is a hydroxy group in which hydrogen is substituted with alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, hetaryl and heterocyclyl, or acyl, or an aminocarbonyl group or an oxycarboyl group; R1a and R1b are hydrogen and alkyl, or R1a and R1b together form a -(CH2) n - polymethylene chain, wherein n=2-5; R1c and R1d are hydrogen and alkyl, or R1c and R1d together form a -(CH2) n - polymethylene chain, wherein n=2-5; R2 is an acyl group, a thioacyl group, a substituted oxycarbonyl group, a substituted amidine group, a substituted aminocarbonyl group, a substituted aminothiocarbonyl group or a sulphonyl group; R3 is hydrogen, C 1 -C 6 alkyl, an alkoxy group, halogen, CF3, CN. |
| priorityDate | 2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.